Beta Pharma Inc. has disclosed antibody-drug conjugates consisting of humanized monoclonal antibody trastuzumab targeting receptor tyrosine-protein kinase erbB-2 (erbB2; HER2) covalently linked to cytotoxic drug through a cleavable linker reported to be useful for the treatment of cancer.
Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported GTPase KRAS (G12D mutant) inhibitors found to be useful for the treatment of non-small-cell lung and pancreatic cancer.
Insilico Medicine Inc. has patented cyclin-dependent kinase (CDK) inhibitors, particularly CDK2/cyclin E1 and/or and CDK4/cyclin D3, reported to be useful for the treatment of cancer.
CAR T-cell therapy has been highly effective in hematologic cancers but faces challenges in solid tumors due to the lack of safe, uniformly expressed surface antigens. A recent study found that the MiT/TFE-family fusion-driven glycoprotein NMB (GPNMB) is highly, homogeneously and stably expressed in primary and relapsed alveolar soft-part sarcoma (ASPS) and translocation renal cell carcinoma (tRCC).
Iksuda Therapeutics Ltd. has obtained IND clearance from the FDA for IKS-04, enabling initiation of a phase I trial in patients with gastrointestinal cancers.
Researchers from Thor Therapeutics Inc. and collaborators reported the efficacy of A-427, a CNS-targeted antisense oligonucleotide (ASO) that selectively suppresses Gfral expression, in preclinical models of cancer-associated cachexia. The brainstem-restricted receptor GFRAL, which mediates the cachexia-inducing effects of tumor-derived GDF15, has emerged as a translational target for therapies designed to counteract tumor-associated wasting and weight loss.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has discovered new peroxisome proliferator-activated receptor γ (PPARγ) modulators potentially useful for the treatment of bladder cancer.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. have disclosed new fibroblast activation protein-α (FAPα) inhibitors covalently linked to radiolabeled chelating agents through a linker potentially useful for the treatment of cancer, inflammatory, cardiovascular disorders and more.
Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) are highly expressed in prostate tumors and exhibit greater prostate specificity than other prostate cancer antigens, reducing the risk of off-target immune responses. Researchers from Theravectys SA and Institut Pasteur reported preclinical efficacy data for Lenti-PROST-02, a novel lentiviral immunotherapy encoding immunogenic regions of PAP and PSA for the treatment of prostate cancer.
RSS
